These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 4040422

  • 1. Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy.
    Webb KS, Ware JL, Parks SF, Walther PJ, Paulson DF.
    Cancer Treat Rep; 1985 Jun; 69(6):663-72. PubMed ID: 4040422
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Specific cytotoxicity of a human immunoglobulin-directed Fab'-ricin A chain conjugate.
    Raso V, Griffin T.
    J Immunol; 1980 Dec; 125(6):2610-6. PubMed ID: 7430640
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
    Webb KS, Poulton SH, Liberman SN, Walther PJ.
    J Urol; 1989 Aug; 142(2 Pt 1):425-32. PubMed ID: 2787412
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human colon adenocarcinoma cell line.
    Griffin TW, Haynes LR, DeMartino JA.
    J Natl Cancer Inst; 1982 Oct; 69(4):799-805. PubMed ID: 6956757
    [Abstract] [Full Text] [Related]

  • 14. Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures.
    Colombatti M, Nabholz M, Gros O, Bron C.
    J Immunol; 1983 Dec; 131(6):3091-5. PubMed ID: 6139402
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal antibody PR92 with restricted specificity for tumor-associated antigen of prostate and breast carcinoma.
    Kim YD, Robinson DY, Tomita JT.
    Cancer Res; 1988 Aug 15; 48(16):4543-8. PubMed ID: 3396007
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
    Sinha AA, Sackrison JL, DeLeon OF, Wilson MJ, Gleason DF.
    Anat Rec; 1996 Aug 15; 245(4):652-61. PubMed ID: 8837723
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.